Eledon Pharmaceuticals (ELDN) Operating Leases (2019 - 2026)

Eledon Pharmaceuticals (ELDN) has 8 years of Operating Leases data on file, last reported at $186000.0 in Q1 2026.

• Quarterly Operating Leases fell 66.49% year-over-year to $186000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186000.0 (down 66.49% YoY) and the FY2025 annual result came in at $283000.0, down 55.78% from the prior year.
• Operating Leases declined to $186000.0 in Q1 2026, from $283000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $640000.0 in Q4 2024 to a low of $83000.0 in Q3 2023.
• A 5-year average of $350133.3 and a median of $350000.0 in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases surged 924.44% — and 2023, when it slumped 82.0%.
• Tracing ELDN's Operating Leases over 5 years: stood at $383000.0 in 2022, then slumped by 78.33% to $83000.0 in 2023, then soared by 671.08% to $640000.0 in 2024, then plunged by 55.78% to $283000.0 in 2025, then plunged by 34.28% to $186000.0 in 2026.
• The last three Operating Leases figures came in at $186000.0 (Q1 2026), $283000.0 (Q4 2025), and $376000.0 (Q3 2025), per Business Quant data.